Implementation science enters global pediatric oncology as the survival gap widens
Each year, about 400,000 children develop cancer, yet survival still depends heavily on where a child lives. In high-resourced health systems, roughly 80% of children with cancer survive; in low-resource settings, survival remains below 30%. Those numbers frame the central problem in this BMJ Open protocol: effective therapies already exist, but access, delivery, and durability remain uneven across settings.
The protocol positions implementation science as the discipline best suited to that gap. Rather than asking only whether an intervention works, implementation science examines how to make it work in real clinics, under real staffing constraints, across health systems with limited infrastructure. In pediatric oncology, that means confronting delays in diagnosis, referral bottlenecks, inconsistent treatment delivery, supply instability, and local barriers that can erase the benefit of otherwise evidence-based care.
The paper proposes a scoping review to map how implementation science has been used in global paediatric oncology and to identify what remains unstudied. The aim is not to test a therapy or compare clinical outcomes in children directly. It is to catalogue the methods, settings, barriers, facilitators, and implementation outcomes that have already been published, then use that evidence base to guide future research planning.
Mapping evidence across oncology systems, not just oncology trials
The review is designed around the Population, Concept, Context framework and follows Arksey and O’Malley guidance together with the PRISMA-ScR checklist. That methodological choice fits the problem. Pediatric cancer care in low- and middle-income countries is shaped by context at every step: referral networks, pathology access, medication availability, family travel burdens, workforce capacity, and the ability of hospitals to sustain protocols over time. A scoping review can capture that spread more effectively than a narrowly defined efficacy review.
Investigators searched MEDLINE, Embase, Scopus, Global Index Medicus, and SciELO from database inception through 6 March 2026. The breadth of that search matters because implementation research in pediatric oncology may appear in oncology journals, global health journals, public health outlets, and regional databases that are often missed by more conventional searches. Two reviewers will independently screen titles and abstracts, then extract predefined data from full texts.
The protocol does not specify a clinical intervention under study. Instead, it treats the evidence ecosystem itself as the subject. Which implementation strategies recur? Which health-system barriers are most often described? Which implementation outcomes are measured? Which regions are represented, and which are absent? Those questions are operational, not abstract. A treatment that is effective on paper still fails when it cannot be delivered consistently, safely, or at scale.
Why pediatric oncology needs an implementation framework
Childhood cancer care is especially sensitive to implementation failure because delays compound quickly. Diagnosis can be slowed by nonspecific symptoms and limited awareness. Once a child reaches care, treatment may depend on pathology confirmation, drug access, radiation availability, infection control, blood product support, and continuity of follow-up. Any weak link can shift a potentially curable disease into a fatal one.
Implementation science provides a structure for studying those weak links. It asks what blocks uptake, what supports adoption, and what helps an intervention survive beyond a pilot phase. In settings where resources are constrained, the best intervention may still fail if it is too complex, too expensive, or too dependent on specialized personnel. A protocol like this is valuable because it recognizes that scaling pediatric oncology is not only a matter of exporting protocols from wealthy countries; it requires adaptation to local systems and measurement of whether the adapted strategy actually takes hold.
A single sentence captures the clinical stakes: survival gains are lost when care cannot be implemented reliably.
What the review will and will not answer
This is a protocol, so it establishes scope rather than findings. No patient-level outcomes are reported, and no clinical effectiveness claims are being made. The review will analyze published data only, with no human participants involved, which is why ethical approval is not required.
The planned output is a map of the literature, not a meta-analysis of treatment effect. That distinction is important because the field remains heterogeneous. Implementation studies may differ by country income level, cancer type, health system structure, intervention design, and outcome framework. Some may focus on referral improvement, others on treatment adherence, supportive care, workforce training, or system navigation. A scoping design is suited to that variation because it can identify patterns across diverse study types without forcing premature statistical aggregation.
The final review will also help define where research is missing. If studies cluster in a small number of regions or focus on a narrow range of implementation strategies, then the resulting agenda can prioritize underrepresented settings and more durable scale-up models. For a field where childhood cancer survival remains so sharply stratified by geography, the location of the evidence is almost as important as the evidence itself.
Ethics, dissemination, and the next research agenda
Because the project relies entirely on published literature, it carries no direct participant risk. The final review is intended for submission to an open-access scientific journal, which should widen access for clinicians, implementation researchers, and policy teams working in resource-limited oncology programs.
The most immediate value of the protocol lies in how it reframes the global pediatric cancer problem. The challenge is not simply identifying therapies with efficacy. It is understanding how to move those therapies into practice, keep them there, and adapt them to settings where staffing, supply chains, and infrastructure are constrained.
That framework also sets a high bar for future studies. If implementation outcomes are not measured, scale-up remains guesswork. If context is ignored, even well-designed interventions may fail outside the original site. The planned review is meant to make those gaps visible and to support an international research agenda that is anchored in the realities of pediatric oncology delivery rather than in efficacy data alone.